investig
whether
pretransplant
immunosuppress
caninespecif
rabbit
antithymocyt
globulin
atg
combin
suboptim
dose
gy
total
bodi
irradi
tbi
would
permit
engraft
canin
dog
leukocyt
antigenident
marrow
cumul
atg
dose
mgkg
produc
tcell
deplet
log
peripher
blood
lymph
node
serum
level
atg
peak
day
initi
therapi
becam
undetect
day
result
canin
antibodi
respons
atg
atg
prolong
allogen
skin
graft
surviv
day
n
compar
day
control
dog
p
five
dog
given
marrow
transplant
atg
mgkg
gy
tbi
posttransplant
immunosuppress
consist
mycophenol
mofetil
cyclosporin
dog
show
initi
engraft
maximum
donor
chimer
level
howev
dog
achiev
sustain
engraft
reject
graft
durat
engraft
rang
week
median
week
compar
histor
control
given
atg
rang
week
median
week
p
total
nucleat
cell
dose
marrow
graft
highest
correl
coeffici
durat
engraft
p
conclud
administ
atg
otherwis
suboptim
condit
dose
gy
tbi
fail
secur
uniform
stabl
hematopoiet
engraft
antithymocyt
globulin
total
bodi
irradi
hematopoiet
cell
transplant
dog
r
diaconescu
et
al
develop
nonmyeloabl
regimen
hematopoiet
cell
transplant
hct
dog
leukocyt
antigen
dla
ident
canin
litterm
consist
condit
gy
total
bodi
irradi
tbi
short
cours
postgraft
immunosuppress
mycophenol
mofetil
mmf
cyclosporin
csp
regimen
success
translat
clinic
trial
patient
thought
high
risk
toxic
convent
myeloabl
regimen
major
role
pretransplant
tbi
model
seem
host
immunosuppress
rather
creation
marrow
space
graft
home
success
stabl
allograft
could
also
achiev
gy
irradi
cervic
thorac
upper
abdomin
lymph
node
chain
substitut
gy
tbi
prompt
stabl
engraft
donor
cell
document
nonirradi
marrow
lymph
node
space
recipi
dog
tbi
condit
dose
decreas
gy
initi
uniform
allogen
engraft
seen
dog
eventu
lost
graft
despit
mmf
csp
show
delic
immunolog
balanc
host
donor
attempt
establish
stabl
allograft
gy
tbi
met
mix
success
substitut
immunosuppress
agent
sirolimu
mmf
postgraft
yield
transient
engraft
pretransplant
use
novel
immunosuppress
agent
even
though
caus
profound
peripher
blood
lymphocytopenia
howev
stabl
graft
condit
gy
tbi
seen
recipi
dog
sensit
marrow
donor
intraven
iv
inject
peripher
blood
mononuclear
cell
pbmc
concurr
blockag
costimulatori
signal
inject
fusion
peptid
result
valid
continu
search
immunosuppress
agent
less
toxic
could
substitut
tbi
antithymocyt
globulin
atg
mixtur
polyclon
antibodi
potent
immunosuppress
effect
atg
use
combin
reducedintens
nonmyeloabl
condit
regimen
allogen
hct
studi
ask
whether
rabbit
anticanin
atg
given
gy
tbi
would
facilit
stabl
engraft
marrow
dlaident
donor
recipi
administ
brief
cours
postgraft
mmf
csp
marrow
graft
studi
preced
pharmacokinet
skin
graft
studi
atg
dose
aim
reduc
peripher
blood
tcell
count
baselin
valu
litter
beagl
minimongrel
crossbre
either
rais
fred
hutchinson
cancer
research
center
fhcrc
seattl
wa
purchas
commerci
kennel
dog
observ
diseas
least
day
studi
dog
enrol
veterinari
prevent
medicin
program
includ
routin
anthelmint
standard
immun
seri
canin
distemp
parvoviru
adenoviru
type
parainfluenza
viru
coronaviru
rabi
addit
intraderm
dose
customprepar
formalininactiv
canin
papilloma
viru
vaccin
administ
dog
weigh
kg
median
kg
elev
enclos
run
use
hous
dog
maintain
social
group
wherev
possibl
studi
approv
institut
anim
care
use
committe
fhcrc
fulli
accredit
associ
assess
accredit
laboratori
anim
care
intern
dla
match
perform
use
highli
polymorph
major
histocompat
complexassoci
class
class
ii
microsatellit
marker
sequenc
caninespecif
rabbit
atg
provid
sangstat
medic
corpor
fremont
ca
produc
inocul
rabbit
canin
thymocyt
obtain
neonat
immunoglobulin
g
ig
fraction
rabbit
serum
isol
adsorpt
protein
column
cryopreserv
concentr
mgml
ph
atg
thaw
use
filter
membran
administ
undilut
studi
dog
subcutan
sq
iv
premed
given
endotoxin
measur
show
endotoxin
unit
per
millilit
monoclon
antibodi
mab
specif
canin
kindli
provid
dr
peter
moor
school
veterinari
medicin
univers
california
davi
antibodi
canin
kindli
provid
dr
richard
nash
fhcrc
mab
produc
purifi
biolog
product
facil
fhcrc
primari
mab
unconjug
fluorescein
isothiocyan
fitc
conjug
biotinyl
accord
standard
protocol
correspond
isotyp
control
antibodi
use
parallel
case
red
blood
cell
lyse
use
hemolyt
buffer
contain
ethylenediaminetetraacet
acid
white
blood
cell
wash
cold
hank
buffer
salt
solut
hbss
supplement
heatinactiv
hors
serum
primari
mab
ad
gml
l
cellular
suspens
contain
approxim
million
cell
per
millilit
incub
minut
dark
secondari
antibodi
use
streptavidinphycoerythrin
sape
caltag
burlingam
ca
goat
antimous
southern
biotechnolog
associ
birmingham
al
goat
antirabbitp
caltag
ad
gml
wash
incub
ident
last
wash
cell
resuspend
heatinactiv
hors
serum
supplement
propidium
iodid
exclud
dead
cell
analyz
fluorescenceactiv
flow
cytomet
becton
dickinson
san
jose
ca
determin
number
cell
circul
cell
per
microlit
white
blood
cell
count
multipli
percentag
cell
determin
flow
cytometri
specif
atg
batch
assess
stain
blood
healthi
donor
atg
serum
atgtreat
dog
cell
detect
stain
cellbound
atg
goat
antirabbitp
normal
rabbit
igg
dako
glostrup
denmark
use
neg
control
pbmc
dlamismatch
unrel
dog
use
respond
stimul
cell
pbmc
resuspend
waymouthiscov
medium
supplement
heatinactiv
pool
normal
dog
serum
nonessenti
amino
acid
sodium
pyruv
lglutamin
respond
cell
per
well
irradi
gy
stimul
cell
per
well
cocultur
quintupl
roundbottom
plate
day
humidifi
co
air
atmospher
serial
dilut
atg
sera
atgtreat
dog
ad
mix
leukocyt
reaction
mlr
final
atg
concentr
rang
gml
normal
rabbit
igg
use
neg
control
day
cultur
puls
ci
mbq
hthymidin
hour
harvest
hthymidin
uptak
measur
mean
count
per
minut
replic
use
counter
packard
bioscienc
meriden
ct
enzymelink
immunosorb
assay
use
measur
serum
atg
level
briefli
polyvinyl
plate
coat
goat
antirabbit
igg
dako
block
nonfat
milk
phosphatebuff
salin
incub
serum
treat
dog
dilut
bound
atg
detect
horseradish
peroxidaseconjug
goat
antirabbit
igg
pierc
rockford
il
secondari
antibodi
color
reagent
acid
sigma
st
loui
mo
plate
read
vmax
microtit
plate
reader
molecular
devic
menlo
park
ca
nm
standard
curv
establish
known
concentr
atg
sera
dog
infus
serv
control
similar
procedur
use
detect
antirabbit
antibodi
except
plate
coat
dilut
atg
bound
antibodi
detect
horseradish
peroxidaseconjug
goat
antidog
igm
chain
igg
icn
aurora
oh
distinguish
isotyp
titer
antidog
igg
within
atg
prepar
determin
follow
plate
coat
normal
dog
igg
jackson
immuno
research
west
grove
pa
atg
ad
serial
dilut
bound
antibodi
reveal
horseradish
peroxidaseconjug
goat
antirabbit
igg
normal
rabbit
igg
use
neg
control
lymph
node
cell
quantifi
dog
poplit
lymph
node
surgic
sampl
contralater
lymph
node
sampl
atg
administr
half
specimen
fix
embed
paraffin
section
stain
hematoxylineosin
antihuman
antibodi
dako
specif
intracytoplasm
portion
chain
highli
crossreact
canin
molecul
remain
half
node
weigh
minc
rpmi
fetal
calf
serum
filter
elimin
macroscop
debri
total
number
cell
present
final
suspens
determin
use
stain
flow
cytometri
analysi
number
cell
per
gram
lymph
node
tissu
calcul
addit
dog
assess
immun
respons
rabbit
atg
well
sheep
red
blood
cell
srbc
research
diagnost
inc
flander
nj
control
immunogen
methotrex
mtx
given
addit
immunosuppress
inhibit
product
canin
antirabbit
antibodi
two
dog
receiv
atg
mgkgd
day
dose
mtx
mgkg
iv
day
day
srbc
ml
suspens
given
iv
day
sera
collect
week
hemagglutinin
titer
well
dog
antirabbit
antibodi
titer
measur
surgic
biopsi
protocol
previous
describ
skin
graft
perform
dlamismatch
unrel
dog
atg
given
recipi
mgkg
day
mg
kgd
day
day
skin
graft
unrel
autolog
control
skin
graft
transplant
simultan
remov
dress
day
skin
graft
examin
daili
sign
inflamm
day
reject
determin
occurr
erythema
edema
epiderm
reaction
confirm
case
histolog
particular
attent
cellular
infiltr
distort
epiderm
architectur
recipi
administ
gy
tbi
cgymin
highenergi
linear
acceler
clinac
varian
palo
alto
ca
marrow
aspir
donor
gener
anesthesia
long
needl
insert
humeri
infus
iv
within
hour
tbi
marrow
graft
contain
total
nucleat
cell
per
kilogram
median
total
nucleat
cell
per
antithymocyt
globulin
allogen
nonmyeloabl
canin
hct
kilogram
cell
per
kilogram
median
cell
per
kilogram
cell
per
kilogram
median
cell
per
kilogram
tabl
dog
receiv
standard
postgraft
care
immunosuppress
consist
csp
mgkg
twice
day
oral
day
day
combin
mmf
mgkg
twice
day
sq
day
day
csp
level
measur
least
weekli
result
use
csp
dose
adjust
mmf
dose
adjust
accord
clinic
toxic
hematopoiet
engraft
assess
document
donor
dinucleotid
tetranucleotid
variabl
number
tandem
repeat
vntr
polymorph
cell
peripher
blood
marrow
use
polymeras
chain
reaction
pcr
base
assay
previous
describ
sampl
drawn
weekli
month
everi
week
granulocyt
mononuclear
cell
mnc
fraction
isol
blood
ficol
gradient
centrifug
specif
graviti
dna
extract
chimer
also
assess
least
unfraction
marrow
sampl
among
circul
cell
sort
fluorescenceactiv
cell
sort
pcr
amplif
inform
radioact
label
vntr
primer
perform
pcr
product
analyz
gel
electrophoresi
percentag
donor
chimer
recipi
determin
visual
approxim
autoradiographi
respons
atgtreat
mlr
cultur
control
compar
use
wilcoxon
ranksum
test
median
durat
mix
chimer
estim
kaplanmei
method
durat
mix
chimer
compar
histor
control
use
logrank
test
associ
cell
dose
graft
mix
chimer
durat
evalu
spearman
rank
correl
coeffici
report
p
valu
side
consid
signific
atg
specif
white
blood
cell
healthi
dog
incub
atg
prepar
concentr
gml
figur
sera
dog
receiv
cumul
dose
mgkg
atg
sq
sera
drawn
atg
day
first
atg
inject
serum
atg
level
time
point
gml
respect
figur
show
atg
bound
white
blood
cell
howev
atg
bind
affin
cell
fluoresc
intens
stain
doubleposit
cell
approxim
log
higher
cell
peposit
fitcneg
cell
atg
prepar
also
contain
antibodi
crossreact
canin
igg
titer
mix
leukocyt
reactiv
atg
differ
concentr
rang
gml
normal
rabbit
igg
neg
control
ad
mlr
without
complement
figur
thymidin
uptak
significantli
decreas
low
atg
concentr
gml
p
unchang
highest
concentr
gml
p
pharmacokinet
studi
five
dog
administ
atg
dosefind
approach
receiv
marrow
graft
first
dog
receiv
atg
mgkg
iv
day
consecut
day
associ
sever
side
effect
resembl
septic
shock
thereaft
sq
rout
use
addit
dog
receiv
atg
mgkg
day
cumul
dose
rang
mgkg
premed
use
side
effect
seen
serum
level
atg
dog
peak
gml
day
proport
total
dose
administ
becam
undetect
day
case
figur
show
atg
serum
level
total
peripher
blood
lymphocyt
tcell
count
dog
given
cumul
dose
mgkg
effect
atg
lymphocyt
baselin
peripher
blood
tcell
count
atg
administr
tcell
count
declin
dog
reach
nadir
concurr
peak
serum
atg
figur
cell
reduc
equal
peripher
blood
b
cell
reduc
lesser
extent
neutrophil
platelet
red
blood
cell
affect
data
shown
observ
dosedepend
effect
atg
cell
lymph
node
biopsi
dog
receiv
atg
mgkg
show
approxim
tcell
deplet
day
compar
baselin
assess
flow
cytometri
morpholog
figur
peripher
blood
show
tcell
nadir
cell
per
microlit
baselin
level
respect
basi
find
atg
dose
mgkg
use
hct
result
tcell
nadir
approxim
baselin
cell
per
microlit
skin
graft
five
dog
given
atg
skin
transplant
dlamismatch
unrel
donor
assess
immunosuppress
properti
atg
batch
reject
graft
median
day
rang
day
significantli
longer
histor
concurr
control
given
atg
n
reject
unrel
skin
graft
median
day
rang
day
p
wilcoxon
ranksum
test
autolog
skin
graft
surviv
indefinit
five
dog
given
hct
dlaident
donor
either
litterm
n
sibl
anoth
litter
n
tbi
gy
marrow
infus
given
day
atg
administ
day
cumul
dose
mgkg
median
mgkg
tabl
serum
atg
level
peak
gml
median
gml
becam
undetect
day
cell
reach
pretransplant
nadir
cell
per
microlit
median
cell
per
microlit
atg
therapi
tlymphocyt
count
declin
median
approxim
also
declin
median
platelet
count
tbi
tlymphocyt
count
remain
week
return
preatg
level
median
absolut
neutrophil
count
rang
throughout
first
week
transplant
return
refer
rang
platelet
count
nadir
day
level
approxim
full
recoveri
engraft
dog
show
prompt
initi
engraft
donor
chimer
level
reach
peak
median
granulocyt
median
mnc
postgraft
immunosuppress
discontinu
week
figur
b
four
dog
reject
graft
week
hct
without
evid
cytopenia
fifth
dog
remain
mix
chimera
week
followup
donor
contribut
granulocyt
mnc
median
durat
engraft
dog
week
similar
among
histor
control
given
atg
median
week
p
logrank
test
transplantrel
toxic
hematolog
toxic
gener
mild
figur
neutropenia
episod
infect
thrombocytopenia
moder
median
platelet
nadir
l
day
dog
experienc
sever
thrombocytopenia
nadir
l
requir
transfus
cell
reach
first
nadir
day
second
nadir
around
day
recoveri
start
discontinu
immunosuppress
week
reach
preatg
valu
around
week
hct
tcell
chang
dog
reject
similar
dog
sustain
engraft
main
nonhematolog
toxic
gastrointestin
includ
transient
anorexia
weight
loss
diarrhea
like
due
mmf
graftversushost
diseas
observ
marrow
cell
dose
chimer
tabl
show
dog
sustain
engraft
receiv
largest
marrow
cell
dose
analysi
total
nucleat
cell
cell
dose
administ
show
total
nucleat
cell
dose
statist
signific
spearman
correl
coeffici
durat
engraft
p
prompt
observ
shorterthananticip
atg
halflif
antibodi
respons
atg
measur
dog
given
either
skin
graft
n
hct
n
figur
antibodi
rabbit
atg
began
appear
day
first
atg
dose
titer
increas
atg
clear
circul
host
immun
respons
predominantli
igg
isotyp
titer
significantli
higher
igm
antibodi
note
skingraft
anim
atg
level
peak
day
decreas
afterward
antibodi
neutral
becom
almost
undetect
day
even
though
atg
schedul
administ
day
hct
recipi
antirabbit
igg
contribut
atg
clearanc
day
observ
prompt
us
studi
immun
respons
atg
srbc
addit
dog
immunosuppress
mtx
administ
atg
abrog
product
canin
antibodi
mtx
chang
immun
respons
atg
compar
previou
dog
receiv
atg
alon
antirabbit
atg
antibodi
appear
day
first
atg
dose
consist
mostli
igg
antibodi
howev
neither
dog
show
detect
antibodi
respons
srbc
use
control
neoantigen
data
shown
marrow
graft
dlaident
canin
litterm
almost
uniformli
success
condit
subleth
dose
gy
tbi
recipi
given
postgraft
immunosuppress
mmfcsp
regimen
success
translat
clinic
treat
human
patient
malign
nonmalign
hematolog
diseas
howev
engraft
dog
gy
tbi
uniformli
transient
suggest
delic
immunolog
balanc
result
previous
publish
tbi
dose
deescal
studi
allow
us
estim
residu
host
tcell
popul
dog
given
gy
tbi
respect
schwartz
storb
unpublish
data
studi
undertaken
assumpt
pretransplant
atg
would
reduc
host
tcell
number
manner
equival
gy
tbi
concern
howev
residu
atg
might
advers
affect
graft
donor
cell
therebi
impair
engraft
concern
turn
unfound
surprisingli
recipi
dog
mount
igg
anti
atg
antibodi
respons
promptli
clear
agent
circul
time
hct
despit
despit
profound
lymphocytopenia
lymph
node
deplet
cell
transplant
dog
eventu
reject
graft
extend
period
mix
donorhost
chimer
result
significantli
differ
dog
condit
gy
tbi
without
atg
explain
current
failur
sustain
engraft
dog
studi
likelihood
tcell
deplet
achiev
rabbit
atg
insuffici
assum
estim
tcell
deplet
gy
tbi
respect
correct
residu
host
cell
favor
sustain
engraft
model
wherea
host
cell
assum
next
reduct
host
cell
rabbit
atg
combin
pretransplant
atg
gy
tbi
result
estim
residu
host
tcell
popul
approxim
thu
atg
plu
gy
tbi
fell
short
residu
host
cell
estim
gy
tbi
permit
sustain
engraft
dog
studi
clear
dog
show
sustain
engraft
although
possibl
explan
might
fortuit
match
import
minor
histocompat
locu
present
unabl
determin
minor
histocompat
antigen
vitro
test
characterist
atg
prepar
could
interf
immunosuppress
effect
exampl
inhibitori
vitro
effect
mlr
lost
higher
atg
concentr
might
due
presenc
atg
antibodi
mitogen
activ
direct
rel
high
content
endotoxin
endotoxin
unit
per
milligram
igg
besid
immunosuppress
import
compon
hct
quantiti
composit
hematopoiet
cell
administ
success
engraft
gy
tbi
achiev
model
marrow
transplant
combin
granulocyt
colonystimul
factormobil
donor
pbmc
analysi
larger
total
nucleat
cell
number
show
trend
toward
longer
durat
engraft
suggest
marrow
cell
might
facilit
engraft
dosedepend
manner
similar
mechan
clinic
hct
studi
use
myeloabl
regimen
marrow
transplant
relat
unrel
donor
larger
total
nucleat
cell
dose
associ
better
leukemiafre
surviv
pharmacokinet
studi
reveal
atg
clear
circul
neutral
antibodi
within
day
similar
observ
nonhuman
primat
model
clinic
studi
hct
atg
persist
day
transplant
human
patient
given
hct
often
immunosuppress
prior
chemotherapi
therefor
humor
antibodi
product
might
impair
comparison
healthi
experiment
anim
might
explain
longer
halflif
atg
clinic
report
antibodi
respons
atg
characterist
secondari
immun
respons
rapid
kinet
also
product
antibodi
igg
isotyp
latter
observ
corrobor
studi
host
produc
antiatg
antibodi
igg
isotyp
dog
present
studi
expos
atg
first
time
howev
mount
secondari
immun
respons
reconcil
fact
propos
follow
explan
shown
atg
contain
rabbit
antibodi
crossreact
canin
igg
igg
also
found
membranebound
form
bcell
antigen
receptor
miggbcr
possibl
atg
crossreact
miggbcr
trigger
b
cell
effect
signal
pathway
lead
activ
prolifer
effici
product
igg
antibodi
turn
might
atg
complementar
might
lead
neutral
clearanc
atg
hypothesi
indirectli
support
observ
made
dog
receiv
mtx
attempt
suppress
antiatg
immun
respons
antibodi
respons
neoantigen
srbc
complet
suppress
howev
magnitud
antibodi
respons
atg
compar
seen
previou
dog
consist
secondari
immun
respons
affect
mtx
conclus
rabbit
atg
produc
estim
tcell
deplet
dog
howev
degre
tcell
deplet
suffici
compens
delet
gy
tbi
condit
dog
eventu
reject
marrow
graft
atg
trigger
strong
immun
respons
immunocompet
host
result
rapid
clearanc
circul
rs
prize
josef
steiner
krebsstiftung
bern
switzerland
rs
fb
associ
assist
nation
fund
scientif
research
belgium
author
grate
dr
roland
buelow
elizabeth
squir
sangstat
medic
corpor
fremont
ca
gift
atg
oral
cyclosporin
respect
dr
sabin
hadulco
roch
bioscienc
nutley
nj
gift
mycophenol
mofetil
author
would
also
like
thank
marina
lesnikova
phd
assist
flow
cytometri
mlr
studi
erlinda
santo
support
enzymelink
immunosorb
assay
georg
e
sale
md
perform
patholog
studi
michael
harkey
phd
clonal
analysi
core
part
vntr
studi
michel
spector
dvm
alix
joslyn
technician
canin
facil
fred
hutchinson
cancer
research
center
dr
dellagnola
bethg
mielcarek
burrough
georg
nash
kiem
particip
weekend
treatment
staci
zellmer
serina
gisburn
dla
type
technician
hematolog
patholog
laboratori
fred
hutchinson
cancer
research
center
